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Gene expression profiling was performed on liver biopsies from 28 patients (12 HCV and 16 HCV/HIV infected) in an attempt to understand
the mechanisms of HCV liver disease in the presence and absence of HIV coinfection. The data were compared with clinical observations and a
gene expression database obtained for transplant HCV-infected samples. This is the first report of functional genomics being used to compare
intrahepatic gene expression profiles of HCV- and HCV/HIV-infected individuals. Significantly, the intrahepatic global gene expression profiles
do not differ between HCV- and HCV/HIV-infected individuals. However, a subset of patients was identified who share a specific pattern of gene
expression, termed the enhanced gene expression (EGE) pattern. Specifically, the EGE (+) patients show a dramatic decreased expression of
multiple genes associated with the FAS-apoptosis pathway and increased expression of lymphocyte adhesion molecules and lymphocyte-specific
genes. The EGE (+) patients also have partially impaired Type I and II IFN-mediated antiviral responses, including a lack of induction of the anti-
fibrogenic cytokine IFN-γ. Importantly, the pattern of gene expression observed in EGE (+) patients has similarities to patients who developed
fibrosis within 1 year of receiving a liver transplant.
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Chronic infection with hepatitis C virus (HCV) is associated
with an increased risk for the development of fibrosis, cirrhosis,
and hepatocellular carcinoma (HCC). The progression of liver
disease is typically slow, with cirrhosis occurring 20–30 years
after initial exposure to HCV. HCV and human immunodefi-
ciency virus (HIV) coinfection is common, presumably due to
similar routes of transmission. Due to the success of highly
active antiretroviral therapy (HAART), HCV/HIV coinfected
individuals have an increased life expectancy and are now⁎ Corresponding author. Fax: +1 206 732 6055.
E-mail address: kathiw@u.washington.edu (K.-A. Walters).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.02.030experiencing HCV-associated liver disease. The impact of HIV
on the natural history of chronic HCV infection remains unclear.
Some evidence suggests that HIV coinfection is associated with
more severe and more rapid progression of liver disease
(Garcia-Samaniego et al., 1997; Benhamou et al., 1999; Soto et
al., 1997; Graham et al., 2001), while other studies indicate that
HIV coinfection does not significantly impact HCV-associated
liver disease (Monto and Dove, 2004).
Genomic analysis of liver samples provides a unique
opportunity to study HCV–host interactions in an in vivo
setting and obtain relevant information regarding the immune-
system-mediated mechanisms of HCV pathogenesis and liver
disease. In this study, core needle liver biopsies from 28
patients were used to analyze gene expression profiles of
454 K.-A. Walters et al. / Virology 350 (2006) 453–464HCV-infected individuals with and without HIV infection in
an attempt to understand the mechanisms of HCV liver
disease in the presence and absence of HIV coinfection. The
experiments were analyzed in the context of an extensive
expression array database comprised of human clinical
samples, including both HCV-infected and uninfected liver
material (Smith et al., 2003a, 2003b). The current study
describes the analysis of a specific gene expression pattern
that may be associated with HCV-induced pathogenesis in
HCV-infected and HCV/HIV-coinfected individuals. This
pattern also has similarities to the gene expression profiles
in transplant patients who progress to fibrosis within 1 year of
transplant (Smith et al., 2006).
Results and discussion
Characterization of patient cohort
The patient cohort included HCV-infected (n = 12) and
HCV/HIV-infected (n = 16) individuals. The clinical and
virological information for all patients is shown in Tables 1
and 2, respectively. A subset of the samples was obtained
from a tissue repository for which some clinical information,
including serum and liver HIV/HCV levels and patient
outcome, were not available. This also necessitated the useTable 1
Clinical characteristics of patient cohort
C, Caucasian, AA, African American, H, Hispanic, IDU, intravenous drug abuse, Y
ND, not done, EGE, Enhanced gene expression.
* and ** Inflammation and fibrosis were scored using the Batts–Ludwig criteria (sho
Index (HAI) (shown in blue text, Grade: 1–18, Stage: 1–6). (For interpretation of the
of this article.)of two scoring systems for inflammation and fibrosis (Table
1). All patients were treatment naïve with respect to HCV
therapy at the time of biopsy. As the focus of this study was
to identify host gene expression changes in response to HCV
infection, it was important to confirm the presence of HCV in
the biopsy samples used for the microarray experiments. HCV
(+) strand-specific in situ hybridization (ISH) was performed
on parallel sections of the same liver biopsy specimens from a
subset of patients used for microarray analysis (Chang et al.,
2000). To assess the degree of intrahepatic HCV infection and
replication, strand-specific in situ hybridization (ISH) was
performed on parallel sections of the same liver biopsy
specimens from a subset of patients used for microarray
analysis (Chang et al., 2000). Staining of positive and
negative control cell lines expressing HCV subgenomic
RNAs is illustrated in panels A through C of Fig. 1, while
ISH analysis of naturally occurring HCV RNAs in liver
biopsy specimens from our study subjects is illustrated in
panels D through F of Fig. 1. Vector Red signals indicate that
HCV RNAs were restricted to the cell cytoplasm. HCV
genomic and replicative intermediate RNAs were detected in
94.4 and 76.5% of specimens, respectively (Table 2). Patient
4046 had no evidence of either genomic or replicative
intermediate HCV RNA. This patient also had very little liver
disease, as indicated by the low grade and stage scores,, yes, N, no, ALT, alanine amino transferase, AST, aspartate amino transferase
wn in black text, Grade: 0–4, Stage: 0–4) or Ishak Modified Histology Activity
references to colour in this table legend, the reader is referred to the web version,
Table 2
Virological characteristics of patient cohort
Patient HIV RNA
(copies)
serum a
HCV RNA
(IU) serumb
HCV
genotype
HAART Intrahepatic
HCV RNAc
4018 0.05 826,127 1b 2 NRTI,
2 PI
40
4021 15.694 2,536,440 1a Y 80
4023 N/A 377,576 1b N/A 85
4029 N/A 5,634,425 1a N/A 80
4033 N/A 2,341,980 1a N/A 40
4034 <0.050 1,603,880 1a 3 NRTI,
2 PI
70
4044 15.02 3,525,132 1a Y 60
4046 112.33 6178 1a naïve 0
4055 N/A 1a N/A 40
4056 <0.050 2,433,151 1a naïve 40
4065 N/A 85,875 1a N/A 60
4072 N/A 2,488,850 1a N/A 20
4086 0.075 4,390,707 1a 3 NRTI,
2 PI
90
4506 N/A 1a N/A ND
4016 0.729 668,355 1a Y 80
4042 0.058 340,000 1a Y 70
4040 23.36 7,375,660 1a naïve 10
4028 203.52 1,796,480 1a naïve 60
10033 N/A ND N/A ND
10232 ND Y ND
10236 N/A ND N/A ND
10342 N/A ND N/A ND
10388 N/A ND N/A ND
10465 N/A ND N/A ND
10531 ND Y ND
11052 ND naive ND
11177 1a naive ND
11482 ND naive ND
HAART, highly active antiretroviral therapy, NRTI, nucleoside analogue reverse
transcriptase inhibitor, PI, protease inhibitor, N/A, not applicable, Y, yes, ND,
not determined.
a HIV RNA genomes/ml (×1000).
b HCV RNA genomes/ml.
c Intrahepatic HCV RNAwas quantitated using in situ hybridization for HCV
genomic RNA. Numbers represent the percent of cells which stain positive for
the presence of HCV genomic RNA. For each biopsy, the entire biopsy was
examined under low power and a semi-quantitative value was assigned for
percent of positive cells. Data were recorded using pre-determined cutoff
criteria for percent of positive cells and estimates were averaged for final data
set (Pal et al., submitted).
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The 10,000 series of samples were archived samples for
which it was not possible to perform in situ hybridization or
obtain certain clinical information such as HCV genotype or
viral loads.
HCV- and HCV/HIV-infected individuals show similar global
gene expression profiles
For each experiment, RNA from an individual virus-infected
liver was compared to RNA from the normal reference pool
(pNL). Genes were selected as differentially expressed based on
2 criteria: a greater than 95% probability of being differentially
expressed (P value < 0.05) and a fold change of 2 or greater. A
previous study established that the rate of false positives usingthese criteria is less than 1% of all genes present on the array
(Smith et al., 2003b).
The global gene expression profiles for all 30 experiments
are shown in Fig. 2. For 2 patients, 10,232 and 10,262, 2
experiments were done using the same biopsy sample. In
total, 7053 genes were differentially expressed in at least 2 of
the 30 experiments (patient n = 28). The 2D clustering
analysis clearly shows that HCV- and HCV/HIV-infected
individuals, shown in black and blue text, respectively, do not
cluster as two distinct groups. ANOVA analysis also failed to
identify significant differences between the two groups (data
not shown). The fact that intrahepatic gene expression
profiles of HCV- and HCV/HIV-infected individuals look so
similar suggests that even if liver disease progression is
enhanced in the presence of HIV coinfection, the cellular
mechanism of liver pathology may be similar in both HIV (+)
and HIV (−) patients. No specific pattern could be associated
with clinical characteristics available for the patients,
including stage of liver disease, HCV genotype, CD4, or
CD8 lymphocyte counts.
Identification of a subset of patients that show a specific
pattern of gene expression
Analysis of the global gene expression profiles identified a
subset of 7 experiments (6 individual patients) which
consistently cluster together and demonstrate a common pattern
of gene expression (Fig. 2, yellow box). This group contained
two HCV- and four HCV/HIV-infected individuals. Four had
mild liver disease, and two had severe disease as evidenced by
the inflammation and fibrosis scores. Significantly, all patients
from this group had very high numbers of differentially
expressed genes (Fig. 3A), and so the pattern was termed the
Enhanced Gene Expression (EGE) pattern. ANOVA analysis of
EGE (−) and EGE (+) experiments and subsequent 2D
clustering using the ANOVA gene set clearly distinguishes
the 6 EGE (+) patients (brown text) from the remaining EGE (−)
patients (black text) (Fig. 3B).
This EGE pattern is of particular interest for a number of
reasons. First, the cohort of EGE (+) samples contains mostly
HIV (+) patients. Immune suppression, including that me-
diated by HIV infection, is generally associated with a more
rapid progression of HCV-related liver disease (Einav and
Koziel, 2002). Second, a correlation between more severe liver
disease and higher numbers of differentially expressed genes
has been observed in both HCV- and HBV-infected livers
(Honda et al., 2001). HCV-infected liver transplant patients
who develop fibrosis within the first year post-transplant also
accumulate 2- to 3-fold higher numbers of differentially
expressed genes than other individuals (Smith et al., 2006).
While the majority of patients with the EGE pattern only show
mild fibrosis, this does not necessarily mean that they will not
or are not in the process of progressing to a more advanced
stage of fibrosis. An individual may either maintain a low
grade of fibrosis for decades or may progress to a higher grade
of fibrosis and possibly cirrhosis. In addition, gene expression
changes detected in microarray analysis may accumulate prior
Fig. 1. In situ hybridization (ISH) staining of HCV RNAs in control cell lines (panels A through C) and human liver biopsy specimens (panels D through F). (A) HCV
plus strand RNA in HeLa cells detected with HCVantisense (AS) riboprobe. (B) HCV minus strand RNA in HeLa cells detected with HCV sense (S) probe. (C) HCV
negative HeLa cells stained with AS probe, (D) HCV positive liver specimen stained with AS probe detecting viral genomes. (E) HCV positive liver specimen stained
with S probe detecting viral replicative intermediate RNAs. (F) Liver specimen stained with AS probe (negative results). Positive signal is red; nuclei are
counterstained green. 40× magnification.
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histological level (Smith et al., 2003a). It is possible that this
pattern represents significant cellular events associated with
fibrosis progression. Further analysis of genes will provide
insight into the pathological processes occurring in these
patients.
The EGE pattern is associated with disruption of the
FAS-mediated apoptotic pathway
There is increasing evidence to suggest that liver cell
damage in chronic HCV infection is mediated by apoptosis of
HCV-infected hepatocytes (Bantel and Schulze-Osthoff, 2003;
Kountouras et al., 2003). In particular, FAS-mediated apopto-
sis of HCV-infected hepatocytes appears to play a key role in
the pathogenesis of chronic HCV infection (Bantel and
Schulze-Osthoff, 2003; Hayashi and Mita, 1999; Pianko et
al., 2001; Gremion et al., 2004). Expression of hepatic FAS
mRNA and protein is increased in HCV-infected patients and
correlates with the severity of liver inflammation, fibrosis, and
hepatocyte apoptosis (Hiramatsu et al., 1994; Iio et al., 1998;
Hayashi and Mita, 1999; Ferenbach et al., 1997; Di Martino et
al., 2000; Seishima et al., 1997; Pianko et al., 2001). FAS-
expressing hepatocytes are generally observed in areas of
lymphocyte infiltration and the expression of Fas ligand
(FasL), which binds to and activates FAS, has been detected inthese lymphocytes (Hiramatsu et al., 1994; Fukuzawa et al.,
2001; Hayashi and Mita, 1999). It is speculated that HCV-
specific T cells migrate into the liver, recognize viral antigen in
infected hepatocytes and induce apoptosis of FAS-expressing
hepatocytes.
The expression of genes within the FAS apoptotic
pathway was analyzed in EGE (+) and EGE (−) groups.
The EGE (+) patients show a strong decreased expression of
many of the key genes associated with the FAS pathway,
including FAS, FasL, caspase 9, and the effector caspases 3
and 7 (Fig. 4A). An increased expression of certain genes is
also seen in EGE (+) patients, in particular the genes for
IFLICE, FAP and inhibitor of caspase activated DNase
(ICAD). Interestingly, these genes function to inhibit the
FAS-mediated apoptotic pathway. In contrast, the EGE (−)
experiments show a much less significant effect, both in the
number of genes effected as well as the magnitude of change
in expression level relative to normal liver (Fig. 4B). The
average fold-change of each gene within the EGE (+) and
EGE (−) groups is shown in Table 3. Many of these were
found to be significantly (P value < 0.05) different between
the two groups based on an error-weighted ANOVA
statistical test (indicated by asterisks).
Apoptosis is a process that is normally regulated at the post-
translational level, including proteolytic activation of caspases.
While the gene expression data clearly demonstrate a
Fig. 2. Expression profiles of 7053 genes that were at least 2-fold regulated with a P value ≤0.05 in at least 2 of 30 experiments (patient n = 28). Two-dimensional
hierarchical clustering was done using Resolver System software with an agglomerative algorithm, complete link heuristic criteria, and Euclidean correlation metric.
Green and red colors show decreased and increased levels of mRNA in a HCV-infected individual relative to a pool of normal liver tissue. The color scale indicates the
magnitude of change. HCV- and HCV/HIV-infected individuals are shown in black and blue text, respectively.
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patients, it is difficult to predict what the effect of these gene
expression changes might be with respect to the level of
hepatocyte apoptosis. One interpretation is that the decreased
expression of FAS and caspases and the increased expression of
the anti-apoptotic genes are indicative of increased resistance of
hepatocytes to apoptosis. Alternatively, the decreased expres-
sion could be the result of enhanced FAS-mediated apoptosis
and subsequent elimination of a subset of cells expressing FAS
from the liver (dead cells do not contribute RNA to the sample).
In this scenario, the increased expression of anti-apoptotic genes
may reflect surviving cells that were able to resist FAS-mediated
apoptosis because they expressed higher levels of these
proteins.
The EGE pattern is associated with increased immune cell
infiltration/activation
Chronic HCV infection is often associated with an increased
infiltration of lymphocytes into the liver (Nuti et al., 1998; Wald
et al., 2004; Shields et al., 1999; Valiante et al., 2000). Indeed,
an increased expression of a number of lymphocyte markers
indicates an increase in infiltrating intrahepatic lymphocytes in
the majority of the liver biopsies. However, the infiltration
appears to be more prominent in the EGE (+) experiments
compared to the EGE (−) experiments. Fig. 5 shows the average
fold change of each gene within the EGE (+) and EGE (−)groups. The EGE (+) patients show a significant (2-fold or
higher) increased expression of a number of genes that are
known to function as adhesion molecules for lymphocytes,
including ICAM-1, 2, 3, LAP1 and ITGAL (Fig. 5A, black
bars). In contrast, the EGE (−) patients show only a small
increased expression or even decreased expression of these
genes (Fig. 5A, grey bars). While the expression of some of
these genes is not exclusive to lymphocytes, the increased
expression is consistent with an increase in the recruitment of
lymphocytes into the liver.
A more prominent increased expression of numerous
lymphocyte-specific genes is also observed in the EGE (+)
samples (Fig. 5B, black bars). As these genes are not normally
expressed in hepatocytes, an increase in their expression likely
indicates an increase in infiltrating lymphocytes. In particular,
there is an increased expression of the B lymphocyte-specific
genes, including CD22 and CD84, as well as cytotoxic T
lymphocytes (CTLs) and natural killer (NK) cell-specific
genes (Cathepsin W, TCR-beta, TNFSF5 and CD53). These
CTLs are of particular interest as they are primarily
responsible for mediating apoptosis of hepatocytes via
FasL–FAS interaction.
The expression of genes specifically associated with
activated T cells, particularly CD8 (+) CTLs, shows a similar
trend. The data suggest a higher prevalence of activated
lymphocytes in the EGE (+) compared to EGE (−) samples, as
indicated by a strong increased expression of IL2RA,
Fig. 3. (A) Number of differentially expressed genes in individual liver biopsies (at least 2-fold regulated, P value ≤0.05. (B) Expression profiles of sequences
identified by ANOVA analysis of EGE (+) and EGE (−) individuals. Two-dimensional hierarchical clustering was performed and displayed as described in the legend
to Fig. 1. EGE (+) and EGE (−) individuals are shown in brown and black text, respectively.
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samples (Fig. 5B, black bars). The strong decreased expression
of CTLA4 in EGE (+) samples might actually indicate an
increase in T cell activation as CTLA4 is preferentially
expressed in non-activated T cells and its expression decreases
following lymphocyte activation. Most of the described gene
expression patterns are associated with CTL and NK cell
activation, indicating that these immune cells represent the
majority of activated lymphocytes in the liver. In summary,
these results suggest that there is an increase in the general
intrahepatic lymphocyte population in EGE (+) patients. AsFAS-mediated apoptosis is induced by CTLs, increased levels
of intrahepatic CTLs suggests that the dysregulation of the
FAS pathway in EGE (+) patients is the result of enhanced
hepatocyte apoptosis.
Expression of Type I and II interferon-induced genes in EGE
(+) and EGE (−) patients
Common to all biopsy samples is the evidence of a Type 1
interferon (IFN) response, shown in Fig. 6A. A number of key
IFN-regulated genes are up-regulated in the majority of the
Fig. 4. Expression profiles of genes associated with the FAS-apoptosis pathway
in EGE (+) (A) and EGE (−) (B) experiments. Pathway Builder (Protein
Lounge) and the Pathway feature of Resolver were used to visualize the
expression of genes from the FAS-apoptosis pathway. The expression profiles of
individual genes are shown in boxes and each bar within the box indicates 1
experiment.
Table 3
Average fold change of genes in the FAS mediated
Gene EGE (+) EGE (−)
FasL −0.83 0.77
Fas* −3.08 0.57
FADD 0.35 −0.06
CASP10* 2.8 1.61
CASP8 0.133 0.096
CASP9 −1.92 −0.15
CASP3* −3.13 −0.64
CASP6 1.82 0.69
CASP7* −2.86 1.16
FAP 0.99 −0.04
IFLICE* 1.93 0.32
RIP2* −3.19 −1.68
CAD* 1.46 0.66
ICAD 3.35 0.92
D4-GDI 0.81 0.06
Apoptosis pathway in EGE+ and EGE− patients.
Asterisks indicate genes whose average expression values differ significantly
between EGE (+) and EGE (−) groups (AVONA statistical test, P value <0.05).
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STAT1. Quantitative PCR analysis of a number of the IFN-
regulated genes demonstrated a good correlation with the gene
expression data from the microarrays (Fig. 6B), although the
ratios calculated from real-time PCR generally exceeded those
obtained using microarrays. In general, the level of induction
is similar in all experiments and does not correlate with either
HIV coinfection, stage of liver disease or any other clinical
characteristic. However, there is some evidence that the EGE
pattern may be associated with a partial impairment of theIFN-mediated transcriptional response. Several of the EGE (+)
patients show both strong decreased expression and reduced
induction of several key genes in the IFN signaling pathway
relative to the remaining patients (Fig. 6A, gene names in
blue). Interestingly, transplant patients who develop fibrosis
within 1 year also demonstrate an impaired response to HCV
infection, including a reduced induction of IFN-related genes,
relative to patients who do not develop fibrosis (Smith et al.,
2006).
The EGE (+) patients also show a strong decreased
expression of IFN-GR1 and 2, IL18 (IFN-γ-inducing factor),
IL18R1 as well as a lack of induction of IFN-γ compared to
EGE (−) patients (Fig. 7, shown within the yellow box).
IFN-γ has been shown to be anti-fibrogenic and a recent
report has shown a correlation between decreased IFN-γ
production from T cells and more advanced fibrosis stage in
chronic HCV infection (Watson et al., 2003). Activated CTLs
are the major source of IFN-γ, and it is possible that the
CTLs of EGE (+) patients are impaired in their ability to
produce this cytokine.
Potential clinical relevance of EGE pattern
Due to the extended course of HCV-associated liver disease,
patient clinical outcomes were unknown at the time of the
present study. However, comparison of gene expression profiles
between the patients involved in this study and patients who
received liver transplants due to HCV-associated liver disease
suggests that the EGE pattern may represent cellular events
associated with progressive fibrosis. Certain liver transplant
patients (Fig. 8, patients 509 and 510, blue text) who developed
fibrosis within 15 months of receiving a liver transplant show a
very similar pattern of gene expression and cluster together with
many of the EGE (+) patients (Fig. 8, brown text) (Fig. 8).
Patients 504 and 512 also developed fibrosis but did not
progress as rapidly as patients 509 and 510. Also similar to the
EGE (+) patients, these transplant patients (504, 512, 509, and
Fig. 5. Expression profiles of lymphocyte-associated genes in EGE (+) and EGE (−) experiments. (A) Expression of lymphocyte adhesion molecules. (B) Expression
of lymphocyte-associated genes. Each bar in the graph represents the expression of 1 gene, and results are shown as average fold-change within each group (either EGE
(+) or EGE (−)). Asterisks indicate genes whose average expression values differ significantly between EGE (+) and EGE (−) groups (standard t test, P value ≤0.05).
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and demonstrated an impaired IFN response (Smith et al.,
2006).
Conclusions
Functional genomic analysis of liver biopsies demonstrated
that the global gene expression profiles in HCV- and HCV/HIV-
infected individuals do not differ significantly. This result is
consistent with a recent study conducted in the HAART era in
which 260 patients were followed for an average of 4 years but
did not find a statistically significant difference in either
cirrhosis or death rates due to end-stage liver disease in HCV-
and HCV/HIV-infected patients (Monto and Dove, 2004). The
lack of significant difference in intrahepatic gene expression
also suggests that the mechanism of HCV-associated liver
disease in HIV (−) and HIV (+) patients is similar. The
investigation of intrahepatic and/or peripheral lymphocyte
populations may provide more relevant information regarding
the role of HIV in HCV-associated liver disease.
The analysis of the global gene expression profiles did result
in the identification of a subset of patients who share a pattern of
gene expression which likely represents a specific host responseto HCV infection. The gene expression analysis demonstrated
both a dysregulation of FAS-mediated apoptotic pathway and
increased lymphocyte infiltration in EGE (+) patients, which
suggests increased hepatocyte cell death. These patients also
demonstrate partially impaired Type I and Type II IFN
responses. Detection of HCV (−) strand RNA by ISH
demonstrated that active viral replication was present in the
majority of the patients. No significant difference in the number
of hepatocytes with active HCV replication was observed
between the EGE (+) and EGE (−) patients, but it is possible
that this is related to the fact that only a subset of patient samples
was available for the ISH analysis. The lack of correlation
between the EGE pattern and any known clinical feature or
patient outcome makes it difficult to assess its clinical
relevance. However, a pattern similar to the EGE pattern was
observed specifically in patients who developed fibrosis within
15 months of receiving a liver transplant (Smith et al., 2006).
The transplant patients also accumulated high levels of
differentially expressed genes and demonstrated an impaired
IFN response. While the majority of patients in the EGE (+)
cohort have mild liver disease, an individual with mild fibrosis
may either maintain a low stage of fibrosis indefinitely or may
progress to a higher stage and possibly cirrhosis. Taken
Fig. 6. Expression of genes associated with an interferon response. (A) Expression of genes that were at least 2-fold regulated with a P value ≤0.05 in at least 5 out of
30 experiments. See legend of Fig. 1 for details on clustering, the applied color scheme for the fold changes in the mRNA levels, experiment representation, and gene
names. EGE (+) and EGE (−) patients are shown in brown and black text, respectively. (B) Real-time PCR validation of the expression array data performed for three
IFN-inducible genes (STAT1, IFIT1, IFI44) in a subset of patient liver biopsies.
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cellular events associated with the progression of fibrosis. They
also suggest that the nature of the host innate antiviral immune
response contributes to the progression of liver disease. Future
studies could include experiments with biopsies from patients
with known clinical outcomes to determine if the EGE pattern
can predict disease progression.
Materials and methods
Human liver tissue samples
Core needle liver biopsies were collected from patients at
the University of Washington and John Hopkins University.All patients gave informed consent to protocols approved
by the Human Subjects Review Committee at the University of
Washington and the Internal Review Board at John's Hopkins
University. Normal, uninfected liver tissue from 8 patients
who underwent tumor resection due to metastases of non-liver
origin was collected at the University of Barcelona, Spain.
These uninfected samples were pooled to create a standard
normal liver reference (pNL) that was used for all microarray
experiments.
Total RNA isolation and mRNA amplification
Frozen liver tissues were disrupted in Trizol Reagent
(Invitrogen, Carlsbad, CA) using a Polytron homogenizer
Fig. 7. Expression of cytokine genes. Expression of genes that were at least 2-fold regulated with a P value≤0.05 in at least 5 out of 30 experiments. See legend of Fig.
1 for details on clustering, the applied color scheme for the fold changes in the mRNA levels, experiment representation, and gene names. EGE (+) patients and EGE
(−) individuals are shown in brown and black text, respectively. Th1-associated cytokines are shown in black text while Th2-associated cytokines are shown in purple.
EGE (+) experiments are shown within the yellow box.
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isolated according to the Trizol protocol. All total RNA
samples were double amplified using the RiboAmp RNA
Amplification kit (Arcturus, Mountain View, CA). The quality
of amplified RNA was evaluated by capillary electrophoresis
using an Agilent 2100 Bioanalyzer (Agilent Technologies,
Palo Alto, CA).
Expression Microarray Format and Data Analysis
Microarray format, protocols for probe labeling, hybridiza-
tion, slide treatment, and scanning are described on the web site
http://expression.microslu.washington.edu. Human cDNA set 1
expression arrays carrying 13,026 unique cDNA clones were
purchased from Agilent. A single experiment comparing two
samples, one from a liver with infection and one from the
normal liver reference, was performed with four replicate arrays
using the dye label reverse technique as described before, thus
providing mean ratios between the expression levels of each
gene in the analyzed sample pair, standard deviations, and P
values (Geiss et al., 2001, 2003; Smith et al., 2003a, 2003b). All
data were entered into a custom-designed database, Expression
Array Manager, and then uploaded into Rosetta Resolver
System 4.0 (Rosetta Biosoftware, Kirkland, WA) and Spotfire
Decision Suite 7.1.1 (Spotfire, Somerville, MA). Data normal-
ization and the Resolver System Error model specificallydeveloped for this array format are described on the web site
http://expression.microslu.washington.edu. This web site is also
used to publish all primary data in accordance with the proposed
standards (Brazma et al., 2001).
Quantitative RT-PCR
Quantitative real-time PCR (rtPCR) was used to validate the
gene expression changes. Total RNA samples were treated with
DNA-free DNase Treatment and Removal Reagents (Ambion,
Austin, TX). Reactions were performed in quadruplicate on the
ABI 7500 Real Time PCR System (Applied Biosystems, Foster
City, CA), using TaqMan chemistry with primer and probe sets
selected from the Assays-on-Demand product list (Applied
Biosystems) and two endogenous controls, GAPDH and 18S
ribosomal RNA.
In situ hybridization (ISH)
ISH analysis of HCV genomic and replicative intermedi-
ate RNAs was performed as published previously (Chang et
al., 2000). Briefly, the sections were formalin fixed and
digested with proteinase K (1 μg/ml) and soaked in
equilibration solution followed by incubation in pre-hybrid-
ization buffer (Novagen, Madison, Wisconsin) at 50 °C for
1 h. Sense and anti-sense riboprobes specific for HCV minus
Fig. 8. Expression profiles of 4884 genes that were at least 2-fold regulated with a P value≤0.05 in at least 6 of 39 experiments (patient n = 37). See legend of Fig. 1 for
details on clustering, the applied color scheme for the fold changes in the mRNA levels, experiment representation, and gene names. EGE (+) patients are shown in
brown text, and transplant patients with rapidly progressive fibrosis are shown in blue text. Experiments using samples from the transplant patients involved the
comparison of the baseline biopsy obtained at the time of transplantation and a sample taken from the same patient 12 months after transplantation.
463K.-A. Walters et al. / Virology 350 (2006) 453–464or plus strand RNAs, respectively, were generated by run off
in vitro transcription from HCV 5′NTR, core and envelope 1
(E1) genes in the presence of digoxigenin-UTP (Dig-UTP)
using T3 or T7 polymerase (Boehringer Mannheim Bio-
chemicals, Indianapolis, IN). After subsequent removal of the
DNA template by DNase I, Dig-labeled riboprobes were
further broken down to an average size of 100 nucleotides
by alkaline hydrolysis, applied to sections at a final con-
centration of 4 ng/μl and incubated for approximately 32 h at
50 °C. Post-hybridization washes included treatment with
single strand specific ribonuclease (Roche, 20 μg/ml in 2×
SSC) to eliminate unbound probe, and a 50% formamide
with SSC wash at 65 °C. After blocking, the sections were
incubated with 1:250 dilution of alkaline phosphatase
conjugated anti-digoxigenin Fab fragment (Roche) followed
by Vector red substrate (Vector Laboratories, CA). Sections
were counterstained with 2% methyl green and photographed
using bright-field microscopy. HeLa cells expressing sub-
genomic portions of HCV plus and minus strand RNAs
served as positive controls in ISH experiments usingriboprobes of opposite polarity, while non-transfected Hela
cells and liver biopsy specimens from uninfected subjects
served as negative controls in all experiments. Since the ISH
assay is highly genotype specific, two positive control cell
lines are needed for ISH analysis of HCV RNAs per each
genotype.
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